

Effect of Foods and β -Cyclodextrin on the Bioaccessibility and the Uptake by Caco-2 Cells of Hydroxytyrosol from Either a Pure Standard or Alperujo

Aurélia Malapert, Valérie Tomao, Olivier Dangles, Emmanuelle Reboul

► **To cite this version:**

Aurélia Malapert, Valérie Tomao, Olivier Dangles, Emmanuelle Reboul. Effect of Foods and β -Cyclodextrin on the Bioaccessibility and the Uptake by Caco-2 Cells of Hydroxytyrosol from Either a Pure Standard or Alperujo. *Journal of Agricultural and Food Chemistry*, American Chemical Society, 2018, 66 (18), pp.4614-4620. hal-02022957

HAL Id: hal-02022957

<https://hal-amu.archives-ouvertes.fr/hal-02022957>

Submitted on 18 Feb 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 Research Article

2

3 **Effect of foods and β -cyclodextrin on the bioaccessibility and the uptake by Caco-2 cells of**
4 **hydroxytyrosol from either a pure standard or alperujo**

5

6 Aurélie MALAPERT¹, Valérie TOMAO¹, Olivier DANGLES¹, Emmanuelle REBOUL^{2*}

7

8 ¹University of Avignon, INRA, UMR408 SQPOV, Avignon, France

9 ²INRA, INSERM, Aix-Marseille University, C2VN, Marseille, France

10

11 *Address correspondence to: Emmanuelle REBOUL, UMR 1260 INRA NORT, Faculté de
12 Médecine, 27 boulevard Jean-Moulin, 13385 Marseille Cedex 5 FRANCE.

13 Tel: (+33).4. 91.29.41.03; Fax: (+33).4. 91.78.21.01; E-Mail: emmanuelle.reboul@univ-amu.fr

14

15

16

17

18 **Keywords:** Olive pomace; Bioavailability; Biophenols; Digestion; Intestinal absorption;

19 Enterocyte.

20

21

22 **Abstract**

23 Hydroxytyrosol bioaccessibility and absorption by the intestinal cells have been studied using an
24 *in vitro* digestion model and Caco-2 TC7 monolayers cells in culture, in the presence or absence
25 of β -cyclodextrin and foods. Hydroxytyrosol was either provided as a pure standard or in an
26 alperujo powder. The presence of foods significantly decreased hydroxytyrosol bioaccessibility
27 and absorption (-20% and -10%, respectively), while β -cyclodextrin had no effect. Moreover, the
28 presence of other compounds from alperujo in the intestine compartment reduced hydroxytyrosol
29 absorption by Caco-2 cells compared to pure standard (-60%). The final bioavailability of
30 hydroxytyrosol, defined as its quantity at the basolateral side of cultured cell monolayers compared
31 to the initial amount in the test meal, was $6.9\pm 0.4\%$, $31.1\pm 1.1\%$ and $40.9\pm 1.5\%$ when
32 hydroxytyrosol was from alperujo, or a standard administered with or without food, respectively.
33 Our results show that conversely to foods, β -cyclodextrin does not alter hydroxytyrosol
34 bioavailability.

35

36

37 **Chemical compounds**

38 Hydroxytyrosol (PubChem CID: 82755)

39 β -cyclodextrin (PubChem CID: 444041)

40

41

42 **1 Introduction**

43 Two-phase olive pomace, also called alperujo, is one of the most abundant industrial
44 Mediterranean pollutants. It is produced in large quantity in two-phase centrifuge mills and is
45 composed of olive vegetation water and solid olive pieces ¹. Two-phase centrifuge mills allow
46 reducing the water consumption and then the quantity of olive mill wastes compared to both
47 traditional and three-phase centrifuge systems. Alperujo pollutant character is especially due to its
48 high phenolic content. Interestingly, previous studies have demonstrated the great interest of these
49 phenolic compounds because of their high health benefits ².

50 In order to valorize these co-products, the phenolic composition of alperujo has been extensively
51 characterized, thus confirming that it can be an interesting source of valuable compounds for the
52 nutraceutical, cosmetic and food industries. The major phenolic compounds identified into olive
53 mill wastes were hydroxytyrosol (HT) and tyrosol, both belonging to the phenyl alcohol family,
54 as well as *p*-hydroxycinnamic acids such as caffeic acid and derivatives ^{3, 4}. These molecules
55 display a catechol unit that confers them a reducing (electron-donating) character tightly related to
56 their bioactivity (e.g., their antioxidant potential) ⁵. HT has received a health claim by the European
57 Food Safety Agency (EFSA) due to its high ability to scavenge reactive oxygen species and to
58 reduce the risks of cardiovascular disease ⁶⁻⁸. However, the electron-donating properties of olive
59 phenols make them sensitive to oxidation. Hence, investigating the influence of the food matrix,
60 including food ingredients used for formulation purposes, on the stability and bioavailability of
61 olive phenols is a relevant issue.

62 Cyclodextrins (CDs) are natural cyclic oligosaccharides made of D-glucose units bound by α -1,4
63 linkages and mainly used in the agro-food and pharmaceutical industries to form inclusion
64 complexes (IC) with bioactive compounds, to enhance their stability and solubility ^{9, 10}. β -CD (7
65 D-glucose units) is the most used CD because of its low price, its availability and its ability to

66 form inclusion complexes with a large range of medium-sized compounds (MM < 800 g/mol) ¹¹.
67 β -CD can also be used to facilitate polyphenol extraction from plants, such as resveratrol from
68 grape pomace ¹²⁻¹⁴, and were suggested to be suitable to extract bioactives such as triterpenes from
69 alperujo ¹⁵. However, its ability to interact with polyphenol bioavailability is not known.
70 *In vitro* digestion studies can be carried out to assess the bioaccessibility of a given compound, *i.e.*
71 the fraction of the ingested dose that is transferred from the food matrix to the aqueous phase or to
72 mixed micelles (combining bile acids and lipid digestion products). This fraction is considered as
73 available for subsequent absorption by the enterocytes, which can be investigated using the Caco-
74 2 cell model. Bioaccessibility and intestinal absorption are two critical steps governing a
75 compound bioavailability, *i.e.* the fraction of the ingested dose (native forms + metabolites) that
76 reaches the general blood circulation and/or target tissues ¹⁶.
77 In this work, we investigated the effects of β -CD, alperujo matrix and foods (represented by a test
78 meal containing pureed potatoes, minced beef and refined olive oil) on the bioaccessibility and the
79 intestinal absorption of HT (from a standard powder and from a local alperujo).

80

81 **2 Materials and Methods**

82 2.1. Supplies

83 β -CD was given from Roquette Freres (Lestern, France). HT (purity > 98%) was kindly provided
84 by Pr. Francesco Visioli (IMDEA, Madrid, Spain). Tyrosol and gallic acid were supplied from
85 Sigma-Aldrich Co (St Louis, USA). Pepsin, porcine pancreatin, porcine bile extract, water, formic
86 acid, ethanol and acetonitrile were purchased from Sigma-Aldrich (Fontenay sous Bois, France).
87 Dulbecco's modified Eagle's medium (DMEM) containing 4.5 g/L glucose and trypsin-EDTA (500
88 mg/L and 200 mg/L, respectively), non-essential amino acids, penicillin/streptomycin and PBS
89 were purchased from Life Technologies (Illkirch, France). Fetal bovine serum (FBS) came from

90 PAA (Vélizy Villacoublay, France). Olive pomace was collected from the Castelas mill equipped
91 with a two-phase centrifuge system (Baux-de-Provence, France). Foods were purchased from a
92 local supermarket.

93

94 2.2. Preparation of the alperujo sample

95 Alperujo (Aglandau variety, 72% of moisture, stored in cheesecloth canvas) was manually pressed,
96 then filtered on celite and passed through 0.45 μ m and 0.2 μ m paper filters (VWR). Ethanol was
97 added to a final proportion of 42% to precipitate proteins (removed by centrifugation). After
98 ethanol evaporation under vacuum, the protein-free aqueous phase from alperujo was frozen at -
99 20°C.

100

101 2.3. Preparation of the inclusion complexes

102 In aqueous solution, HT is known to bind β -CD with a 1:1 stoichiometry and a binding constant \approx
103 40 M⁻¹ ¹⁷. Hence, the inclusion complex was prepared from an equimolar solution of HT and β -
104 CD (5 mM) in water. The concentration was chosen high enough to allow a substantial formation
105 of the inclusion complex (\approx 20%), despite the relatively low affinity of HT for β -CD in aqueous
106 solution. The equimolar HT: β -CD solution was stirred at 200 rpm for 1h at room temperature, then
107 freeze-dried. The inclusion complex in a solid form (powder) was kept in amber flask at -20°C
108 until use.

109 The total phenol concentration of the protein-free aqueous phase of alperujo was assessed using
110 Folin-Ciocalteu method and diluted to reach a total phenol concentration of 5 mM in gallic acid
111 equivalent ¹⁸. Then, β -CD was added to the sample in the same concentration and the solution was
112 stirred at 200 rpm for 1h at room temperature. After freeze-drying, the aqueous phase of alperujo

113 + β -CD sample was stored as a powder at -20°C in amber glass. For comparison, an alperujo
114 extract without β -CD was also freeze-dried and store as a powder in similar conditions.

115

116 2.4. Simulated digestion

117 The test meal, when present, was composed of pureed potatoes (6.7 g), cooked minced beef (1.2
118 g) and refined olive oil (0.2 g). HT and alperujo samples with or without β -CD were added so as
119 to reach 7 mg of HT in the meal. The simulated digestion was carried out as described previously
120 (Figure 1) ¹⁹. All analyses were run in quadruplicate. Aliquots from oral, gastric and duodenal
121 steps were taken up and frozen at -80°C until use.

122

123 2.5. Cell culture and uptake experiments

124 The human colon adenocarcinoma cell line Caco-2 TC7 was cultured on transwell membrane (six-
125 well plate, 1 mm pore size polycarbonate membrane; Becton Dickinson) to obtain confluent and
126 differentiated cell monolayers as previously described ²⁰.

127 Cytotoxicity of digestion samples on Caco-2 TC7 was primarily evaluated to determine the
128 suitable dilution of the phenolic aqueous fractions from in vitro digestion in HBSS before adding
129 them to the apical side of cell monolayers. These results showed that 1/20 and 1/10 dilutions were
130 required for HT and alperujo samples, respectively. To avoid any interference with DMEM or
131 serum components, the phenolic aqueous fractions were diluted in HBSS and Caco-2 cells received
132 HBSS in both chambers 12h before the experiments. At the beginning of each experiment, cell
133 monolayers were washed twice with 1 mL of PBS and received 1 mL of diluted aqueous fraction.
134 Finally, cell monolayers were incubated at 37°C for 2h, 4h and 6h. After the incubation period,
135 apical and basolateral solutions were harvested. Cell monolayers were washed twice with 1 mL of
136 PBS and scraped in 0.5 mL of PBS. All samples were stored at -80°C until use.

137

138 2.6. Analyses of HT and alperujo samples

139 2.6.1. Extraction of HT and alperujo samples

140 Phenolic compounds were extracted from salivary, gastric and duodenal steps as follows: 0.3 mL
141 ethanol containing the internal standard was added to 0.2 mL of sample. The internal standards
142 were tyrosol and gallic acid for HT and alperujo samples, respectively, as gallic acid was not found
143 in the alperujo extracts ²¹. n-Hexane (0.2 mL) was then added and the mixture was homogenized
144 for 10 min using a vortex blender at maximal speed. After centrifugation (2500 rpm for 10 min at
145 4°C), the lower phase was collected and the sediment further extracted with 0.3 mL ethanol and
146 additional vortexing for 10 min. The two ethanol phases were pooled, evaporated to dryness using
147 a Speed-Vac®, and the dried extracts dissolved in 200 µL H₂O and frozen at -80°C before analysis.
148 Apical media from cell culture experiments were directly injected **into UHPLC-DAD-MS system**
149 **for analysis**. Basolateral media (1900 µL) were primarily dried using a Speed-Vac® and the
150 residues dissolved in 80 µL H₂O.

151 The PBS fractions containing harvested cells (500 µL) were sonicated with 50 µL of internal
152 standard for 10 min at room temperature and centrifuged at 7000 rpm for 10 min at 4°C ²².
153 Supernatants were recovered and evaporated to dryness, then dissolved in 50 µL H₂O and frozen
154 at -80°C before analysis.

155

156 2.6.2. Chromatographic analysis

157 All extracts were analyzed by UHPLC-DAD-MS using an Acquity UPLC® system linked to both
158 a diode array detector and a Bruker Daltonics HCT Ultra Ion Trap mass spectrometer equipped
159 with an Electron Spray Ionization (ESI) source operating in negative mode. The separation was
160 performed on an Acquity C18 BEH column (50x2.1 mm i.d., 1.7 µm). The solvents were (A)

161 water/formic acid (99.5/0.5) and (B) acetonitrile. For alperujo analyses, the proportions of solvent
162 B used were: 0-10 min: 1-20%, 10-12 min: 20-30%, 12-14 min: 30-100%. The injection volume
163 was 1 μ L for all samples and 10 μ L for cells and basolateral extracts. The column temperature was
164 kept at 35°C. Along the 3 steps of the gradient, the flow rate was 0.30, 0.35 and 0.40 mL/min.
165 Chromatograms were acquired at 280 nm. The spectroscopic detection was performed in the range
166 200-800 nm with a resolution of 1.2 nm. HT concentrations were estimated from a calibration
167 curve (peak area vs. concentration) constructed with HT standard with R² values greater than 0.99.
168 Homovanillyl alcohol and homovanillyl alcohol glucuronide were quantified as HT equivalent ²¹.
169 For HT analyses, the same conditions were used and the flow rate was constant at 0.30 mL/min.
170 The proportions of B were: 0 – 2.4 min: 1-30%, 2.4 – 3 min: 30-100%.

171

172 2.6.3. Mass spectrometry

173 ESI mass spectra were obtained in the following conditions: ionization energy = 50 or 100 eV,
174 capillary voltage = 2 kV, source temperature = 365°C. The drying gas was introduced at a flow
175 rate of 10 L/min and the skimmer voltage was 40V. Scans were performed in the *m/z* range 100 –
176 2000.

177

178 2.6.4. Calculation and statistics

179 All the *in vitro* experiments were run in quadruplicate. Results were expressed as means and
180 standard deviations. Differences between means were assessed using ANOVA followed by the
181 post-hoc Tukey test for parametric data. P values under 0.05 were considered significant. The
182 bioavailability was assessed by the ratio between the amount of phenolic compounds in the
183 basolateral side and the initial amount added to the apical side or to the meal.

184

185 **3 Results**

186 3.1. HT bioaccessibility in the oral, gastric and duodenal compartments

187 The digestion of the HT in the 3 compartments was assessed with free HT and β -CD-bound HT
188 (HTCD). The influence of the meal on HT bioaccessibility was also evaluated with the HTCD
189 complex. Figure 2 shows the percentage of remained HT in each compartment. In the mouth
190 compartment, β -CD seems to act as a protective agent for HT within the meal, HT recovery being
191 87.6 % (\pm 1.2) and 96.4 % (\pm 1.1) for HT and HTCD respectively ($p < 0.0001$). In the absence of
192 food (HTCD-FF), β -CD provided a weaker but still significant protective effect. In the gastric
193 compartment, HT recoveries in this step were 91.3 % (\pm 2.7), 94.9 % (\pm 1.9) and 97.7 % (\pm 2.7)
194 for HT, HTCD and HTCD-FF, respectively. No significant benefit of β -CD was observed.
195 Conversely, the presence of food had a negative effect on HT recovery (HTCD vs HTCD-FF, $p <$
196 0.05). Finally, except for the HTCD condition, the stability of HT was not significantly different
197 in the duodenal compartment at pH 6 compared to the gastric one. The total apparent losses in the
198 aqueous fractions were 37.2 % (\pm 1.0), 33.6 % (\pm 0.9) and 13.5 % (\pm 3.2) for HT, HTCD and
199 HTCD-FF respectively. There was thus no difference regarding HT bioaccessibility between free
200 HT and its β -CD complex. However, the absence of food significantly improved HT
201 bioaccessibility compared to the other conditions ($p < 0.0001$).

202 Figure 3 presents the bioaccessibility of HT from an alperujo powder during the same digestion
203 steps. There was no significant influence of β -CD on HT recovery from alperujo in the different
204 compartments. As for pure HT, no degradation was observed in the mouth while an important loss
205 was observed in the duodenal compartment. HT recovery from alperujo samples in the gastric
206 compartment and in the aqueous phase decreased from 77.2 % (\pm 2.8) to 52.6 % (\pm 2.3) and from
207 76.4 % (\pm 2.7) to 50.3 % (\pm 1.2) for alperujo and alperujo-CD, respectively. Overall, HT recovery

208 from alperujo samples decreased along digestion ($p < 0.0001$). The stability of HT into the alperujo
209 samples appeared less important than for pure HT ($p < 0.001$).

210

211 3.2. HT absorption by Caco-2 TC7 cells

212 The absorption and metabolism of HT were studied using differentiated Caco-2 TC7 cell
213 monolayers. Bioavailability was determined as the quantity of targeted compounds in the
214 basolateral side vs. the initial amount added to the meal. The aqueous fractions obtained from the
215 precedent digestion studies were used to study HT absorption into the enterocytes after a 1/10 or
216 a 1/20 dilution for alperujo and HT samples, respectively. Thus, the cells received about 5.1-5.3,
217 6.0 and 6.7 μg per well of HT from meals containing HT, HTCD or alperujo and from HTCD-FF,
218 respectively. Chromatograms of the different fractions are presented on Figure 4A. UPLC-DAD-
219 MS analyses allowed to identify homovanillyl alcohol (HVA) as a O-methylether metabolite of
220 HT, giving a parent ion $[\text{M}-\text{H}]^-$ at m/z 167 and a fragment ion at m/z 153 (HT). Figure 4 (B, C, D,
221 E panels) shows the quantity of HT and HVA recovered at the apical and basolateral sides of the
222 cells. Each quantity was expressed as a percentage of the initial HT concentration at the apical
223 side. For all conditions, a significant decrease of the HT content was observed at the apical side
224 (more than 85%, $p > 0.05$) after 6h incubation. Concomitantly, a significant increasing quantity of
225 HT was recovered at the basolateral side ($>40\%$). The curve profiles highlight the time-dependent
226 transport of HT from the apical to basolateral side. No significant difference was observed at the
227 basolateral side between the three HT samples. HVA was the only HT metabolite observed in our
228 conditions. It was mainly recovered at the apical side reaching about $32.8 \pm 1.2\%$, $37.5 \pm 4.1\%$ and
229 $40.3 \pm 2.5\%$ of the initial HT content for the HTCD-FF, HTCD and HT conditions, respectively.
230 The lower percentage of HVA that appeared in the aqueous fraction without meal was due to the
231 higher initial quantity of HT in this condition.

232 In the case of HTCD-FF, the initial HT amount was higher (+26%) compared to other conditions.
233 The final HT amounts at the basolateral side were about 2.2 μg for HT and HTCD and 2.9 μg for
234 HTCD-FF, respectively. Thus, the absorption of native HT from HTCD-FF increased over 30%
235 ($p < 0.0001$) compared to conditions containing foods. The transport of HT through the intestinal
236 barrier was also concentration-dependent. The same amount of HVA was approximately produced
237 whatever the initial HT concentration. The amount of native HT at the basolateral side reached
238 $65.7 \pm 2.1\%$, $63.9 \pm 1.4\%$ of the initial apical content for HT and HTCD, and $71.0 \pm 0.8\%$ for HTCD-
239 FF. The analysis of cell contents revealed neither HT nor HT metabolite: more than 99% of HT
240 and its metabolite were recovered in the apical and basolateral compartments.

241 The absorption of HT from alperujo samples by Caco-2 cells was also evaluated, as shown in
242 Figure 5. Chromatograms of the different fractions are presented on Figure 5A. The initial HT
243 amount was around 6 μg per well at the apical side of the cells. The general curve profile indicates
244 a time-dependent transport of HT. No significant difference regarding the amounts of both HT and
245 its metabolite was found between alperujo and alperujo-CD samples in all culture media over time.
246 About $0.88 \pm 0.05 \mu\text{g}$ and $0.91 \pm 0.04 \mu\text{g}$ of HT were recovered at the basolateral side for alperujo
247 and alperujo-CD conditions, respectively. So, $14.4 \pm 0.8\%$ and $15.0 \pm 0.5\%$ of the initial apical
248 HT amount from alperujo samples crossed the cell monolayers ($p > 0.05$). Despite the higher HT
249 load in the alperujo conditions (about 6 μg vs 5.1-5.3 μg for alperujo conditions, HT and HTCD),
250 the amount of HT absorbed was about 2.5-fold less important than for HT and HTCD conditions,
251 *i.e.* the absorption rate decreases by more than 60% ($p < 0.0001$). Homovanillyl alcohol
252 glucuronide (HVA-GlcU) was identified according to its molecular ion $[\text{M-H}]^-$ at m/z 343 and its
253 fragment ions $[\text{M-H-GlcU}]^-$ at m/z 167 (HVA) and 153 (HT), characteristic of the homovanillyl
254 moiety. This HT metabolite was only found in the basolateral compartment and was estimated at
255 $6.7 \pm 0.8\%$ and $7.3 \pm 0.9\%$ of the initial apical HT amount for alperujo and alperujo-CD,

256 respectively. The total amount of unmetabolized HT at the basolateral side was $68.8 \pm 1.5\%$ and
257 $69.8 \pm 2.6\%$ for alperujo and alperujo-CD, respectively. So, β -CD had no significant effect on the
258 HT metabolism rate. In these conditions and conversely to the standard samples, a low amount of
259 HT was recovered into Caco-2 cells. Moreover, the total recovery of HT in these three
260 compartments exceeds 110 % after 6h of incubation ($p < 0.0001$). This may be explained by the
261 fact that a partial metabolization of other compounds from alperujo could generate HT.

262

263 **4 Discussion**

264

265 This work evaluated for the first time in a comprehensive manner the effect of the presence of β -
266 CD and/or foods on both HT bioaccessibility and HT uptake by intestinal cells.

267 The first step of HT digestion occurs in the mouth. Mastication favors interactions between the
268 phenolic compounds, food, saliva and dioxygen. In this compartment, the protective effect of β -
269 CD observed in our study may be linked to its ability to build a protective shell around HT, thereby
270 limiting its contact with potential food prooxidants such as iron species. In the stomach, food
271 disintegration intensifies due to the periodic and synchronized contractions of its wall, the acidic
272 environment and the enzymatic activity²³. The *in vitro* digestion of HT standard confirmed that
273 HT is stable in the acidic conditions of the gastric compartment, which is in accordance with
274 previous data²⁴. The recovery of HT after the gastric step was almost total, in agreement with
275 Pereira-Caro et al. who obtained a recovery rate higher than 99 % in their *in vitro* digestion study
276 without food²⁵. In our work, the small loss (lower than 5%) in the gastric compartment may be
277 due to interactions between HT and the food matrix.

278 In our duodenal conditions, pure HT recovery did not significantly decrease. Several studies have
279 shown that HT was not stable in neutral or mildly alkaline conditions. In their work on the

280 digestion of phenolic compounds from olive oil, Soler et al. observed a loss of HT in alkaline
281 conditions²⁶. Corona et al. also observed that the amounts of HT and its derivatives progressively
282 decreased during digestion by pancreatin (pH 7.5), reaching a total apparent loss of 20.3% after
283 2h for HT. This value took into account the formation of 3,4-dihydroxyphenylacetic acid
284 (DOPAC) as a side-product of HT²⁷. In our cases, no DOPAC formation was observed. We
285 suggest that the total apparent losses in the aqueous fractions were the result of the partition of HT
286 after the centrifugation step.

287 The comparative study of the HT standard and the HTCD sample showed a slight effect of β -CD
288 on the final bioaccessibility of HT. β -CD is mainly used in the pharmaceutical industry to protect
289 bioactive compounds and increase their water solubility and consequently their bioavailability²⁸.
290 As a cyclic starch derivative, β -CD may be partially hydrolyzed during digestion. However *in vivo*,
291 β -CD only partly digested in the upper gastrointestinal tract and can reach the large intestine where
292 it is metabolized by the microflora fermentation^{29,30}. Besides possible β -CD digestion, dilution is
293 the major factor triggering the release of the guest compound from a CD complex³¹. This factor
294 should be very important in our study because HT has only a weak affinity for β -CD (binding
295 constant $< 10^2 \text{ M}^{-1}$ ¹⁷, data not shown). Overall, the bioaccessibility of HT from HTCD was not
296 significantly increased compared to the free HT standard without β -CD.

297 In the absence of food, the bioaccessibility of HT was increased by almost 20% compared to the
298 same sample in the presence of food. Many macromolecular food components can bind phenolic
299 compounds and retain them within the food matrix. In this work, potato is a source of starch, which
300 is known to retain phenolic compounds³². Similarly, beef is rich in proteins, which have a general
301 affinity for phenols^{33,34}. The clear influence of the food matrix on the bioaccessibility of dietary
302 plant phenols such as HT outlines the importance of including real meal components in *in vitro*
303 digestion studies.

304 The study with alperujo samples was carried out in the presence of food. In each compartment,
305 HT from alperujo samples was generally less bioaccessible than from free standard. Indeed,
306 although alperujo samples are protein-free, they contain fibers and sugars, which could interact
307 with the meal components and the digestive enzymes (possibly slowing down protein and starch
308 digestion), thereby reducing the bioaccessibility of phenolic compounds ². The apparent loss of
309 HT bioaccessibility from alperujo powders (compared to the standard) was also higher (+10%).
310 Again, no significant effect of β -CD was observed.

311 Caco-2 TC7 cells were then chosen as a suitable model to follow the absorption of target
312 compounds through the intestinal barrier. HT was brought to the cells as an aqueous fraction
313 obtained from our previous digestion study. The study of HT and its β -CD complex within a meal
314 revealed that HT was largely absorbed through Caco-2 cells and partly metabolized into
315 homovanillyl alcohol due to the catechol-O-methyltransferase (COMT) activity of the enterocytes.
316 Most of the HT recovered at the basolateral side was unmetabolized (over 60%) and HVA was
317 recovered in the two culture media, especially in the apical compartment. These data are in
318 agreement with previous results. Indeed, Manna et al. (2000) observed that 25% of HT reached
319 the basolateral side of Caco-2 cells after 1h, 90% of which being unmetabolized. They also
320 identified HVA as a metabolite. They determined that HT reaches the basolateral side through
321 passive diffusion and that this transport was time- and concentration-dependent ³⁵. Corona et al.
322 also observed 90% of unmetabolized HT at the basolateral side of the cells after the phenolic
323 compounds were added to the apical side from a standard buffered solution ²⁷. Finally, Mateos et
324 al. observed that 59% of HT from apical side (initial concentration = 50 μ M) reached the
325 basolateral side after 4h of incubation, with almost 20% recovered as O-methylether and 80% as
326 unmetabolized HT ³⁶. In our study, for HT, HTCD and HTCD-FF conditions, the transport of
327 unmetabolized HT from the apical to the basolateral side of Caco-2 cells ranged from $25.4 \pm 1.5\%$

328 to $42.3 \pm 0.8\%$ over 2 to 6h. The difference regarding HT absorption rates in our study compared
329 to previous data is likely explained by the fact that HT was just dissolved in an aqueous buffer
330 (HBSS or PBS) in previous studies, while we used a more complex mixture obtained from *in vitro*
331 digestion.

332 In the case of HT from alperujo powders, we observed the appearance of HVA-GlcU as a HT
333 metabolite. Moreover, the transport of HT from the apical to basolateral side ranged from $8.4 \pm$
334 0.6% to $14.7 \pm 0.5\%$ over 2 to 6h. This lower transport rates compared to HT standard conditions
335 can be the result of a competition between HT and other alperujo components to cross the intestinal
336 cells. The same phenomenon was observed when comparing the absorption of pure diosmetin and
337 diosmetin from a rosemary extract ³⁷. Interestingly, a small amount of HT from alperujo was
338 recovered into the harvested Caco-2 cells and the total recovery of HT exceeded 100%. If
339 metabolized, HT-glucoside that is also present in alperujo extract could be a source of HT, which
340 would explain this result.

341 Finally, it is interesting to compare two methods to calculate the *in vitro* bioavailability of HT, by
342 making a ratio with either the initial HT apical content during the absorption experiments (Table
343 1) or the initial HT amount brought via the meal (Table 2). The second method allows to correct
344 the common overestimation of the *in vitro* bioavailability when considering uniquely the
345 absorption step and not the whole digestion process. The second values were decreased by more
346 than 25% and 50% for HT standard and alperujo samples, respectively. This analysis confirmed
347 that HT was more bioavailable when it was brought as a pure standard form than as a plant extract.
348 The absence of food also participated in increasing the final HT bioavailability. HT bioavailability
349 from the alperujo samples was lower, likely because of possible interactions between HT and other
350 alperujo components and/or competition between them for absorption by Caco-2 cells ²⁶.

351

352 In summary β -CD, which can be used to enhance phenol stability during storage, did not modified
353 the bioaccessibility and the bioavailability of HT from alperujo, in the presence or in the absence
354 of foods. It would be interesting to extend this result to modified β -CDs such as 2-hydroxypropyl-
355 β -CD, which can also be used to complex bioactive compounds ¹⁵. Conversely to β -CD,
356 interactions with food components (probably potato starch and beef proteins) were shown to
357 decrease HT bioaccessibility. These interactions had a strong impact on HT final bioavailability,
358 the HT amount absorbed by the intestinal cells being strongly dependent on the bioaccessible HT
359 content. Besides, HT was more bioaccessible and better absorbed by enterocytes from a pure form
360 than from an alperujo powder, in which it likely competes with other phenolic compounds at
361 different steps of the digestion-absorption process. HVA was the only metabolite observed when
362 HT was from a pure standard and HVA-GlcU was detected when HT was provided via alperujo
363 powders. The low bioavailability of HT reflected its high metabolization in the intestine.
364 Our data have dietary significance as plant phenol supplements are usually consumed within a
365 meal and under the form of complex mixtures, rather than individual supplements taken at fast.

366

367 The authors have declared no conflicts of interest.

368

369 **Abbreviations:** β -CD, β -cyclodextrin; HT, hydroxytyrosol; HTCD: HT: β -CD inclusion
370 complex; HTCD-FF: HT: β -CD inclusion complex-food free condition; HVA: homovanillyl
371 alcohol; HVA-GlcU: homovanillyl alcohol glucuronide

372

373 **Acknowledgment:** The authors thank Pr F. Visioli (Madrid, Spain), Moulin de Castelas (Baux de
374 Provence, France) and Roquettes Frères (Lesterm, France) for providing us hydroxytyrosol,
375 alperujo and β -cyclodextrin, respectively. The authors are also grateful to M. Nowicki for her help

376 with cell culture and Dr. B. Gleize (UMR408 SQPOV, France) for her help with statistical
377 analyses.

378

379 **Funding source:** This work was supported by SFR TERSYS, University of Avignon.

380

381 **References**

- 382 1. Niaounakis, M.; Halvadakis, C. P., Olive processing waste management: literature review
383 and patent survey. In *Waste Management Series*, Elsevier: 2006; Vol. Volume 5.
- 384 2. Dermeche, S.; Nadour, M.; Larroche, C.; Moulti-Mati, F.; Michaud, P., Olive mill
385 wastes: Biochemical characterizations and valorization strategies. *Process Biochem* **2013**, *48*,
386 1532-1552.
- 387 3. Ghanbari, R.; Anwar, F.; Alkharfy, K. M.; Gilani, A. H.; Saari, N., Valuable nutrients
388 and functional bioactives in different parts of olive (*Olea europaea* L.)-a review. *Int J Mol Sci*
389 **2012**, *13*, 3291-340.
- 390 4. Leouifoudi, I.; Ziad, A.; Amechrouq, A.; Oukerrou, M. A.; Mouse, H. A.; Mbarki, M.,
391 Identification and characterisation of phenolic compounds extracted from Moroccan olive mill
392 wastewater. *Food Sci Technol* **2014**, *34*, 249-257.
- 393 5. Malapert, A.; Reboul, E.; Dangles, O.; Tomao, V., An overview of the analysis of
394 phenolic compounds found in olive mill by-products. *Trends Chromatogr* **2016**, *10*, 81-94.
- 395 6. Giordano, E.; Dangles, O.; Rakotomanomana, N.; Baracchini, S.; Visioli, F., 3-O-
396 Hydroxytyrosol glucuronide and 4-O-hydroxytyrosol glucuronide reduce endoplasmic reticulum
397 stress in vitro. *Food Funct* **2015**, *6*, 3275-81.
- 398 7. Jemai, H.; El Feki, A.; Sayadi, S., Antidiabetic and antioxidant effects of hydroxytyrosol
399 and oleuropein from olive leaves in alloxan-diabetic rats. *J Agric Food Chem* **2009**, *57*, 8798-
400 804.
- 401 8. Visioli, F.; Bernardini, E., Extra virgin olive oil's polyphenols: biological activities. *Curr*
402 *Pharm Des* **2011**, *17*, 786-804.
- 403 9. Iacovino, R.; Rapuano, F.; Caso, J. V.; Russo, A.; Lavorgna, M.; Russo, C.; Isidori, M.;
404 Russo, L.; Malgieri, G.; Isernia, C., beta-Cyclodextrin inclusion complex to improve

405 physicochemical properties of pipemidic acid: characterization and bioactivity evaluation. *Int J*
406 *Mol Sci* **2013**, *14*, 13022-41.

407 10. Patil, J. S.; Kadam, D. V.; Marapur, S. C.; Kamalapur, M. V., Inclusion complex system;
408 a novel technique to improve the solubility and bioavailability of poorly soluble drugs: a review.
409 *Int J Pharm Sci Rev and Res* **2010**, *2*, 29-34.

410 11. Szejtli, J., Past, present, and future of cyclodextrin research. *Pure Appl Chem* **2004**, *76*,
411 1825-1845.

412 12. Munin, A.; Edwards-Levy, F., Encapsulation of natural polyphenolic compounds; a
413 review. *Pharmaceutics* **2011**, *3*, 793-829.

414 13. Pinho, E.; Grootveld, M.; Soares, G.; Henriques, M., Cyclodextrins as encapsulation
415 agents for plant bioactive compounds. *Carbohydr Polym* **2014**, *101*, 121-135.

416 14. Ratnasooriya, C. C.; Rupasinghe, H. P., Extraction of phenolic compounds from grapes
417 and their pomace using beta-cyclodextrin. *Food Chem* **2012**, *134*, 625-31.

418 15. Lopez-Miranda, S.; Guardiola, L.; Hernandez-Sanchez, P.; Nunez-Delicado, E.,
419 Complexation between oleanolic and maslinic acids with native and modified cyclodextrins.
420 *Food Chem* **2018**, *240*, 139-146.

421 16. Rein, M. J.; Renouf, M.; Cruz-Hernandez, C.; Actis-Goretta, L.; Thakkar, S. K.; da Silva
422 Pinto, M., Bioavailability of bioactive food compounds: a challenging journey to bioefficacy. *Br*
423 *J Clin Pharmacol* **2013**, *75*, 588-602.

424 17. Lopez-Garcia, M. A.; Lopez, O.; Maya, I.; Fernandez-Bolanos, J. G., Complexation of
425 hydroxytyrosol with beta-cyclodextrins. An efficient photoprotection. *Tetrahedron* **2010**, *66*,
426 8006-8011.

- 427 18. Singleton, V. L.; Rossi, J. A., Colorimetry of Total Phenolics with Phosphomolybdic-
428 Phosphotungstic Acid Reagents. *American Journal of Enology and Viticulture* **1965**, *16*, 144-
429 158.
- 430 19. Goncalves, A.; Gleize, B.; Roi, S.; Nowicki, M.; Dhaussy, A.; Huertas, A.; Amiot, M. J.;
431 Reboul, E., Fatty acids affect micellar properties and modulate vitamin D uptake and basolateral
432 efflux in Caco-2 cells. *J Nutr Biochem* **2013**, *24*, 1751-7.
- 433 20. Goncalves, A.; Margier, M.; Tagliaferri, C.; Lebecque, P.; George, S.; Wittrant, Y.;
434 Coxam, V.; Amiot, M. J.; Reboul, E., Pinosresinol of olive oil decreases vitamin D intestinal
435 absorption. *Food Chem* **2016**, *206*, 234-8.
- 436 21. Malapert, A.; Reboul, E.; Loonis, M.; Dangles, O.; Tomao, V., Direct and Rapid
437 Profiling of Biophenols in Olive Pomace by UHPLC-DAD-MS. *Food Analytical Methods* **2017**.
- 438 22. Gallardo, E.; Sarria, B.; Espartero, J. L.; Gonzalez Correa, J. A.; Bravo-Clemente, L.;
439 Mateos, R., Evaluation of the Bioavailability and Metabolism of Nitroderivatives of
440 Hydroxytyrosol Using Caco-2 and HepG2 Human Cell Models. *J Agric Food Chem* **2016**, *64*,
441 2289-97.
- 442 23. Drechsler, K. C.; Ferrua, M. J., Modelling the breakdown mechanics of solid foods
443 during gastric digestion. *Food Res Int* **2016**, *88*, 181-190.
- 444 24. Gómez-Romero, M.; García-Villalba, R.; Carrasco-Pancorbo, A.; Fernández-Gutiérrez,
445 A., Metabolism and Bioavailability of Olive Oil Polyphenols. In *Olive Oil - Constituents*,
446 *Quality, Health Properties and Bioconversions*, Boskou, D., Ed. InTech: 2012.
- 447 25. Pereira-Caro, G.; Sarria, B.; Madrona, A.; Espartero, J. L.; Escuderos, M. E.; Bravo, L.;
448 Mateos, R., Digestive stability of hydroxytyrosol, hydroxytyrosyl acetate and alkyl
449 hydroxytyrosyl ethers. *International journal of food sciences and nutrition* **2012**, *63*, 703-707.

- 450 26. Soler, A.; Romero, M. P.; Macia, A.; Saha, S.; Furniss, C. S. M.; Kroon, P. A.; Motilva,
451 M. J., Digestion stability and evaluation of the metabolism and transport of olive oil phenols in
452 the human small-intestinal epithelial Caco-2/TC7 cell line. *Food Chem* **2010**, *119*, 703-714.
- 453 27. Corona, G.; Tzounis, X.; Dessi, M. A.; Deiana, M.; Debnam, E. S.; Visioli, F.; Spencer,
454 J. P. E., The fate of olive oil polyphenols in the gastrointestinal tract: Implications of gastric and
455 colonic microflora-dependent biotransformation. *Free Radical Res* **2006**, *40*, 647-658.
- 456 28. Fang, Z.; Bhandari, B., Encapsulation of polyphenols – a review. *Trends Food Sci Tech*
457 **2010**, *21*, 510-523.
- 458 29. Flourie, B.; Molis, C.; Achour, L.; Dupas, H.; Hatat, C.; Rambaud, J. C., Fate of beta-
459 cyclodextrin in the human intestine. *J Nutr* **1993**, *123*, 676-80.
- 460 30. *Safety evaluation of certain food additives* World Health Organization: Geneva, 2009.
- 461 31. Shimpi, S.; Chauhan, B.; Shimpi, P., Cyclodextrins: application in different routes of
462 drug administration. *Acta Pharm* **2005**, *55*, 139-56.
- 463 32. Manach, C.; Scalbert, A.; Morand, C.; Remesy, C.; Jimenez, L., Polyphenols: food
464 sources and bioavailability. *Am J Clin Nutr* **2004**, *79*, 727-47.
- 465 33. Bohn, T., Dietary factors affecting polyphenol bioavailability. *Nutr Rev* **2014**, *72*, 429-
466 52.
- 467 34. Jakobek, L., Interactions of polyphenols with carbohydrates, lipids and proteins. *Food*
468 *Chem* **2015**, *175*, 556-67.
- 469 35. Manna, C.; Galletti, P.; Maisto, G.; Cucciolla, V.; D'Angelo, S.; Zappia, V., Transport
470 mechanism and metabolism of olive oil hydroxytyrosol in Caco-2 cells. *FEBS Lett* **2000**, *470*,
471 341-4.

- 472 36. Mateos, R.; Pereira-Caro, G.; Saha, S.; Cert, R.; Redondo-Horcajo, M.; Bravo, L.; Kroon,
473 P. A., Acetylation of hydroxytyrosol enhances its transport across differentiated Caco-2 cell
474 monolayers. *Food Chem* **2011**, *125*, 865-872.
- 475 37. Perez-Sanchez, A.; Borrás-Linares, I.; Barrajon-Catalan, E.; Arraez-Roman, D.;
476 Gonzalez-Alvarez, I.; Ibanez, E.; Segura-Carretero, A.; Bermejo, M.; Micol, V., Evaluation of
477 the intestinal permeability of rosemary (*Rosmarinus officinalis* L.) extract polyphenols and
478 terpenoids in Caco-2 cell monolayers. *PLoS One* **2017**, *12*, e0172063.
- 479
- 480

Tables

Table 1. Bioavailability of phenolic compounds as percentage of HT initial apical amount.

| Samples | HT | HVA | HVA-GlcU |
|-------------|------------|------------|-----------|
| HT | 42.6 ± 2.5 | 22.2 ± 2.5 | |
| HTCD | 41.4 ± 3.0 | 23.4 ± 2.0 | |
| HTCD-FF | 43.0 ± 0.7 | 17.5 ± 0.6 | |
| Alperujo | 14.4 ± 0.8 | | 6.7 ± 0.8 |
| Alperujo-CD | 15.0 ± 0.5 | | 7.3 ± 0.9 |

Values are expressed as mean ± SD of quadruplicate measurements.

Table 2. Bioavailability of the phenolic compounds as percentage of HT initial amount in the test meal.

| Samples | HT | HVA | HVA-GlcU |
|-------------|------------|------------|-----------|
| HT | 31.1 ± 1.1 | 16.2 ± 1.3 | |
| HTCD | 30.9 ± 1.8 | 17.5 ± 1.4 | |
| HTCD-FF | 40.9 ± 1.5 | 16.7 ± 0.6 | |
| Alperujo | 6.9 ± 0.4 | | 3.2 ± 0.3 |
| Alperujo-CD | 7.3 ± 0.3 | | 3.6 ± 0.4 |

Values are expressed as mean ± SD of quadruplicate measurements.

Figure legends

Figure 1. In vitro digestion procedure

HT = hydroxytyrosol, β -CD = β -cyclodextrin.

Figure 2. Bioaccessibility of hydroxytyrosol from standard powder in each digestive compartment

Samples were taken at the beginning of the experiment (T0) and at the end of the oral, gastric and duodenal digestion steps.

HT = hydroxytyrosol standard added to a meal, HTCD = HT- β -cyclodextrine complex added to a meal, HTCD-FF = HTCD complex without food. Values are expressed as mean \pm SD of quadruplicate measurements. Different letters indicate a significant difference according to Tukey test ($p \leq 0.05$) between all conditions for each compartment. Different symbols indicate a significant difference according to Tukey test ($p \leq 0.05$) between all compartments for each condition.

Figure 3. Bioaccessibility of hydroxytyrosol from alperujo powder in each digestive compartment

Samples were taken at the beginning of the experiment (T0) and at the end of the oral, gastric and duodenal digestion steps.

Alperujo = hydroxytyrosol from alperujo. Alperujo-CD = hydroxytyrosol from alperujo phenolic compound - β -cyclodextrine complex. Values are expressed as mean \pm SD of quadruplicate measurements. Different letters indicate a significant difference according to Tukey test ($p \leq 0.05$) between all conditions for each compartment. Different symbols indicate a significant difference according to Tukey test ($p \leq 0.05$) between all compartments for each condition.

Figure 4. Absorption and metabolism by Caco-2TC7 cells of hydroxytyrosol from standard samples

The aqueous fractions obtained from *in vitro* digestion of pure hydroxytyrosol (HT) samples were added to the apical side of cell monolayers. HT and its metabolites were monitored over time.

(A) UHPLC chromatograms of cells culture media: (a) Apical media at T=0h; (b) Apical media at t= 6h; (c) Basolateral media at 6h. HVA = homovanillyl alcohol, IS = internal standard.

(B) Quantity of HT at the apical side; (C) Quantity of HT at the basolateral side; (D) Quantity of HVA at the apical side; (E) Quantity of HVA at the basolateral side. All results are expressed in percent of the initial HT amount at the apical side.

(◆) HT meal; (●) HTCD meal; (▲) HTCD-FF. Values are expressed as mean \pm SD of quadruplicate measurements.

Figure 5. Absorption and metabolism by Caco-2 TC7 cells of hydroxytyrosol from alperujo samples



The aqueous fractions obtained from *in vitro* digestion of alperujo samples were added to the apical side of the cell monolayers. Hydroxytyrosol (HT) and its metabolites were monitored over time.

(A) UHPLC chromatograms of cells culture media: (a) Apical media at T=0h; (b) Cell monolayer content at t=6h; (c) Basolateral media at 6h. HVA-GlcU: homovanillyl alcohol glucuronide, IS = internal standard.

(B) Quantity of HT at the apical side; (C) Quantity of HT and homovanillyl alcohol glucuronide (HVA-GlcU) at the basolateral side; (D) Quantity of HT in the cytosolic compartment of Caco- 2 TC7 cells. All results are expressed in percent of the initial HT amount at the apical side. (●)

HT from alperujo, (◆) HT from alperujo-CD; (▲) HVA-GlcU from alperujo (■) HVA-GlcU from alperujo-CD. Values are expressed as mean \pm SD of quadruplicate measurements.

Figure 1



Test meal and/or pure HT or HT from alperujo complexed or not with β -CD



pH 4



pH 6



Isolation of the aqueous phase from the digesta

Oral phase
NaCl solution +
artificial saliva
10 min under
agitation at 37°C

Gastric phase
+ pepsine
30 min under
agitation at 37°C

Duodenal phase
+ bile
+ pancreatine
30 min under agitation
at 37°C

Figure 2




Figure 3




Figure 4








Figure 5

